Bio-Path Holdings Inc.

3.52-0.5000-12.44%Vol 95.58K1Y Perf -41.40%
Jun 28th, 2022 16:00 DELAYED
BID3.51 ASK3.61
Open4.05 Previous Close4.02
Pre-Market- After-Market-
 - -  - -%
Target Price
11.00 
Analyst Rating
Strong Buy 1.00
Potential %
212.50 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
14.14 
Earnings Rating
Sell
Market Cap25.20M 
Earnings Date
12th Aug 2022
Alpha0.04 Standard Deviation0.91
Beta1.74 

Today's Price Range

3.204.05

52W Range

2.688.62

5 Year PE Ratio Range

-2.60-2.60

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
3.61%
1 Month
13.24%
3 Months
6.07%
6 Months
-4.51%
1 Year
-41.40%
3 Years
-69.98%
5 Years
-95.10%
10 Years
-94.71%

TickerPriceChg.Chg.%
BPTH3.52-0.5000-12.44
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.46-0.47-2.17
Q04 2021-0.32-0.59-84.38
Q03 2021-0.33-0.2912.12
Q02 2021-0.40-0.2635.00
Q01 2021-0.50-0.4314.00
Q04 2020-0.78-0.5726.92
Q03 2020-0.83-0.803.61
Q02 2020-0.89-0.5538.20
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.50-8.70Negative
9/2022 QR-0.50-8.70Negative
12/2022 FY-1.89-7.39Negative
12/2023 FY-1.60-18.52Negative
Next Report Date12th Aug 2022
Estimated EPS Next Report-0.50
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume95.58K
Shares Outstanding7.16K
Shares Float7.15M
Trades Count367
Dollar Volume343.84K
Avg. Volume61.08K
Avg. Weekly Volume88.31K
Avg. Monthly Volume44.81K
Avg. Quarterly Volume50.13K

Bio-Path Holdings Inc. (NASDAQ: BPTH) stock closed at 4.02 per share at the end of the most recent trading day (a 2.55% change compared to the prior day closing price) with a volume of 231.75K shares and market capitalization of 25.20M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 9 people. Bio-Path Holdings Inc. CEO is Peter H. Nielsen.

The one-year performance of Bio-Path Holdings Inc. stock is -41.4%, while year-to-date (YTD) performance is 6.63%. BPTH stock has a five-year performance of -95.1%. Its 52-week range is between 2.68 and 8.6199, which gives BPTH stock a 52-week price range ratio of 14.14%

Bio-Path Holdings Inc. currently has a PE ratio of -2.40, a price-to-book (PB) ratio of 1.26, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -41.03%, a ROC of -41.83% and a ROE of -43.71%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Bio-Path Holdings Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.50 for the next earnings report. Bio-Path Holdings Inc.’s next earnings report date is 12th Aug 2022.

The consensus rating of Wall Street analysts for Bio-Path Holdings Inc. is Strong Buy (1), with a target price of $11, which is +212.50% compared to the current price. The earnings rating for Bio-Path Holdings Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bio-Path Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bio-Path Holdings Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 39.04, ATR14 : 0.20, CCI20 : 189.51, Chaikin Money Flow : 0.05, MACD : 0.17, Money Flow Index : 89.85, ROC : 12.92, RSI : 70.67, STOCH (14,3) : 69.31, STOCH RSI : 1.00, UO : 55.82, Williams %R : -30.69), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bio-Path Holdings Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Bio-Path Holdings Inc.

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.

CEO: Peter H. Nielsen

Telephone: +1 832 742-1357

Address: 4710 Bellaire Boulevard, Bellaire 77401, TX, US

Number of employees: 9

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

52%48%

Bearish Bullish

58%42%

News

Stocktwits